Evidence map›Paper›PMID 20160038›Full record

ArticleCancer research2010

hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Harvey I Pass, Chandra Goparaju, Sergey Ivanov, Jessica Donington, Michele Carbone, Moshe Hoshen, Dalia Cohen, Ayelet Chajut, Shai Rosenwald, Harel Dan and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Review
  7. Sex differences in asbestos exposure.Frontiers in public health · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. MicroRNAs - novel biomarkers for malignant pleural effusions.Contemporary oncology (Poznan, Poland) · 2019
    Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Harvey I PassThoracic Surgery, NYU Langone Medical Center, New York, New York 10016, USA. harvey.pass@med.nyu.edu
Chandra Goparaju
Sergey Ivanov
Jessica Donington
Michele Carbone
Moshe Hoshen
Dalia Cohen
Ayelet Chajut
Shai Rosenwald
Harel Dan
Sima Benjamin
Ranit Aharonov
Rosetta Genomics (Israel) · ILCancer Research Center · USNYU Langone Health · USUniversity of Hawaii System · USUniversity of Hawaiʻi at Mānoa · US

Funding

The North American Mesothelioma ConsortiumU01CA111295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUFLEJT, MARGARET ELISABETH, PASS, HARVEY IRA · 2005 to 2016
$4.8M
NCI NIH HHS U01CA1111295NCI NIH HHS U01 CA111295
6 · The paper itself

Abstract

The inability to forecast outcomes for malignant mesothelioma prevents clinicians from providing aggressive multimodality therapy to the most appropriate individuals who may benefit from such an approach. We investigated whether specific microRNAs (miR) could segregate a largely surgically treated group of mesotheliomas into good or bad prognosis categories. A training set of 44 and a test set of 98 mesothelioma tumors were analyzed by a custom miR platform, along with 9 mesothelioma cell lines and 3 normal mesothelial lines. Functional implications as well as downstream targets of potential prognostic miRs were investigated. In both the training and test sets, hsa-miR-29c* was an independent prognostic factor for time to progression as well as survival after surgical cytoreduction. The miR was expressed at higher levels in epithelial mesothelioma, and the level of this miR could segregate patients with this histology into groups with differing prognosis. Increased expression of hsa-miR-29c* predicted a more favorable prognosis, and overexpression of the miR in mesothelioma cell lines resulted in significantly decreased proliferation, migration, invasion, and colony formation. Moreover, major epigenetic regulation of mesothelioma is mediated by hsa-miR-29c* and was shown through downregulation of DNA methyltransferases as well as upregulation of demethylating genes. A single miR has the potential to be a prognostic biomarker in mesothelioma, and validation of these findings as well as investigation of its downstream targets may give insight for potential therapies in the future.

Indexed as

AdultAgedAged, 80 and overAsbestosCell Line, TumorFemaleHumansMaleMesotheliomaMicroRNAsMiddle AgedPleural NeoplasmsPrognosisReproducibility of ResultsReverse Transcriptase Polymerase Chain ReactionTransfectionAsbestosMicroRNAsMIRN29a microRNA, human

Identifiers

PMID20160038
PMCPMC2831149
OpenAlexW2030596204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.